AU8784698A - Method of using selective parp inhibitors to prevent or treat neurotoxicity - Google Patents

Method of using selective parp inhibitors to prevent or treat neurotoxicity

Info

Publication number
AU8784698A
AU8784698A AU87846/98A AU8784698A AU8784698A AU 8784698 A AU8784698 A AU 8784698A AU 87846/98 A AU87846/98 A AU 87846/98A AU 8784698 A AU8784698 A AU 8784698A AU 8784698 A AU8784698 A AU 8784698A
Authority
AU
Australia
Prior art keywords
prevent
parp inhibitors
selective parp
treat neurotoxicity
neurotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU87846/98A
Inventor
Jun Bao
Ted M Dawson
Valina L Dawson
Mikael J. Eliasson
Patricia D. Hurn
Allen S. Mandir
Andrew Pieper
Kenji Sampei
Solomon H. Snyder
Richard J. Traystman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU8784698A publication Critical patent/AU8784698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
AU87846/98A 1997-08-15 1998-08-14 Method of using selective parp inhibitors to prevent or treat neurotoxicity Abandoned AU8784698A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5586697P 1997-08-15 1997-08-15
US60055866 1997-08-15
US92257597A 1997-09-03 1997-09-03
US08922575 1997-09-03
PCT/US1998/016959 WO1999008680A1 (en) 1997-08-15 1998-08-14 Method of using selective parp inhibitors to prevent or treat neurotoxicity

Publications (1)

Publication Number Publication Date
AU8784698A true AU8784698A (en) 1999-03-08

Family

ID=26734713

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87846/98A Abandoned AU8784698A (en) 1997-08-15 1998-08-14 Method of using selective parp inhibitors to prevent or treat neurotoxicity

Country Status (2)

Country Link
AU (1) AU8784698A (en)
WO (1) WO1999008680A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2004528376A (en) 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Isoquinolinone derivatives as PARP inhibitors
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2500888C (en) 2002-10-01 2010-07-13 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
CA2507027C (en) * 2002-11-22 2012-05-08 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
US7217709B2 (en) 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005113540A1 (en) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation Isoquinoline compound and pharmaceutical use thereof
KR20070116011A (en) 2005-02-25 2007-12-06 이노텍 파마슈티컬스 코포레이션 Tetracyclic amino and carboxamido compounds and methods of use thereof
EP1937268A4 (en) 2005-08-24 2009-07-22 Inotek Pharmaceuticals Corp Indenoisoquinolinone analogs and methods of use thereof
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (en) 2006-10-17 2008-05-31 Kudos Pharm Ltd SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS
JP2010520220A (en) 2007-02-28 2010-06-10 イノテック ファーマシューティカルズ コーポレイション Indenoisoquinolinone analogs and methods of use thereof
EP2188278A1 (en) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinone derivatives
UY31603A1 (en) 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
HUP0800414A2 (en) * 2008-07-04 2010-10-28 Pecsi Tudomanyegyetem Pharmaceutical combination
ME02640B (en) 2008-10-07 2017-06-20 Kudos Pharm Ltd Pharmaceutical formulation 514

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity

Also Published As

Publication number Publication date
WO1999008680A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
AU8784698A (en) Method of using selective parp inhibitors to prevent or treat neurotoxicity
PL330995A1 (en) Substituted pyridines as selective inhibitors of cyclooxygenase-2
PL326420A1 (en) Inhibitors of rotamase enzymatic activity
HUP9900065A3 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
PL327569A1 (en) Promedications of thrombosin inhibitors
GB9624258D0 (en) Inhibitors of rotamase enzyme activity
LT98002A (en) Inhibitors of rotamase enzyme activity
AU6578998A (en) Method of treatment of migraine
AU5920500A (en) System and method for real-time reporting of advertising effectiveness
HUP0200749A3 (en) Substituted benzimidazoles and their use as parp inhibitors and process for their preparation
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
PL330841A1 (en) Benzosulphonic derivatives, method of obtaining them and therapeutic agents containing such derivatives
PL317930A1 (en) Oxalydine compounds, method of obtaining them and therapeutic agents
ZA988017B (en) Parp inhibitors pharmaceutical compositions comprising same and methods of using same
PL331920A1 (en) Spirocyclic inhibitors of metaloproteases
PL342076A1 (en) Method of treating surfaces
PL335378A1 (en) Derivatives of inverse hydroxamates as metaloprotease inhibitors
EP0958275A4 (en) Selective inhibitors of prostaglandin endoperoxide synthase-2
PL334975A1 (en) Application of gasto-intestinal lipase inhibitors
AU5463099A (en) Inhibitors of redox signaling and methods of using same
EP0994707A4 (en) Inhibitors of naaladase enzyme activity
HUP0101640A3 (en) Certain thoil inhibitors of endothelin-converting enzyme
PL324034A1 (en) Tribenzimidazoles useful as inhibitors of topoisomerase i
IL129604A0 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase